<DOC>
	<DOCNO>NCT02400333</DOCNO>
	<brief_summary>This study open-label , randomise , four-period , four-treatment , crossover study healthy male female non-childbearing potential subject , perform single study centre . The objective study assess bioavailability ticagrelor orodispersible ( OD ) tablet administered water , without water suspend water administer nasogastric tube , compare ticagrelor immediate-release ( IR ) tablet</brief_summary>
	<brief_title>Study Assess Bioavailability Ticagrelor OD Tablet vs. IR Tablet</brief_title>
	<detailed_description>Study evaluate bioavailability ticagrelor OD tablet administer water , without water suspend water administer nasogastric tube , compare ticagrelor IR tablet .</detailed_description>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Healthy male female subject age 18 55 year suitable vein cannulation repeat venepuncture . Females must negative pregnancy test screen admission clinical unit , must lactate , must nonchildbearing potential , confirm screen fulfil one follow criterion : Postmenopausal define amenorrhoea least 12 month follow cessation exogenous hormonal treatment folliclestimulating hormone ( FSH ) level postmenopausal range Documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . Have body mass index ( BMI ) 18.5 29.9 kg/m2 inclusive weigh least 50 kg 100 kg inclusive . Able understand , read speak German language . History clinically significant disease disorder , opinion investigator , may either put potential subject risk participation study , influence result potential subject 's ability participate study . Any abnormality alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , gammaglutamyl transpeptidase ( GGT ) , urea , creatinine , thyroidstimulating hormone ( TSH ) , International Normalised Ratio ( INR ) , activate partial thromboplastin time ( aPTT ) , white blood cell ( WBC ) count , haemoglobin ( Hb ) platelet count . Any abnormal haematology , clinical chemistry , coagulation urinalysis result , judge unacceptable deviation consider clinically significant investigator . Any clinically significant abnormal finding vital sign , judge investigator . screen baseline ( Day 1 Treatment period 1 ) , define : Systolic blood pressure &lt; 90mmHg ≥ 140 mmHg Diastolic blood pressure &lt; 50mmHg ≥ 90 mmHg Pulse &lt; 50 &gt; 85 beat per minute ( bpm ) Current smoker smoke used nicotine product within previous 3 month . History haemophilia , von Willebrand 's disease , lupus anticoagulant , diseases/syndromes either alter increase propensity bleed . A personal history vascular abnormality include aneurysm ; personal history severe haemorrhage , hematemesis , melena , haemoptysis , severe epistaxis , severe thrombocytopenia , intracranial haemorrhage ; rectal bleeding within 1 year prior screening ; history suggestive peptic ulcer disease ; discretion investigator . History clinically significant nontraumatic bleed clinically significant bleeding risk , judge investigator . Use aspirin , ibuprofen , nonsteroidal antiinflammatory drug ( NSAIDs ) , drug know increase propensity bleed 2 week randomisation . Platelet count le 150 x 109/L . Criteria applicable insertion nasogastric tube : History severe midface trauma and/or recent nasal surgery . History coagulation abnormality , oesophageal varix stricture , recent band cautery oesophageal varix , and/or alkaline ingestion , discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ticagrelor orodispersible tablet</keyword>
	<keyword>ticagrelor immediate-release tablet</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>Phase I</keyword>
	<keyword>healthy subject</keyword>
</DOC>